Comparative Analysis of Clinical and Medication Information between Chronic Hepatitis B Patients with Damp Heat Syndrome and Spleen Deficiency Syndrome
Table 1
Baseline analysis of 812 CHB patients with DH syndrome and the SD syndrome.
DH (n = 429)
SD (n = 383)
Statistics
Gender (male, %)
326 (75.99%)
213 (55.61%)
0.889a
0.346
Age (years)
44.44 (37.1, 54.61)
44.06 (36.22, 51.38)
−1.887
0.059
Treatment
Antiviral therapy
259 (60.37%)
231 (60.31%)
0.000a
0.986
Recent anti-virus
60 (23.34%)
51 (22.76%)
0.023a
0.881
Antivirus duration (days)
325 (96, 758.5)
370.5 (101, 1074.5)
−1.378
0.168
Hepatoprotective drugs
258 (60.13%)
253 (66.05%)
3.037
0.081
Immunomodulator
15 (3.49%)
4 (1.04%)
5.324a
0.021
Drugs that promote bile excretion
46 (10.72%)
28 (7.31%)
2.844a
0.092
Chinese herbal medicine
108 (25.65%)
99 (25.84%)
0.048a
0.826
Anti-fibrosis proprietary Chinese medicine
18 (4.19%)
21 (5.48%)
0.733a
0.392
Untreated
81 (18.88%)
70 (18.27%)
0.049a
0.825
Liver function value
TBIL (μmol/L)
16.6 (12.5, 22.47)
15.7 (12.47, 21.08)
−1.119
0.263
DBIL (μmol/L)
4.4 (3.3, 6.7)
4.4 (3.03, 6.3)
−0.994
0.32
ALT (U/L)
44 (26, 92.5)
40.8 (23.3, 79.75)
−1.977
0.048
AST (U/L)
36 (26.02, 60.75)
33 (24, 56)
−2.25
0.024
GGT (U/L)
29.85 (18, 65.5)
28 (17.77, 55.25)
−1.352
0.176
ALP (U/L)
79 (64, 100)
75.15 (63, 96)
−1.617
0.106
ALB (g/L)
45.5 (43, 47.8)
45.4 (42.62, 48.1)
−0.315
0.753
Pre-Alb (g/L)
241 (178, 290)
237.35 (180, 288.5)
−0.043
0.966
TBA (μmol/L)
7.6 (3.9, 14)
5.9 (2.9, 12.8)
−2.749
0.006
Hepatitis B virus
HBeAg positive (%)
227 (53.53%)
186 (49.33%)
1.410a
0.235
HBV-DNA (IU/mL)
13020 (0, 2270000)
7181 (0, 2115000)
−1.245
0.213
Liver fibrosis value
APRI
0.48 (0.31, 0.91)
0.46 (0.27, 0.80)
−1.429
0.153
FIB-4
1.63 (1.07, 2.77)
1.52 (1.01, 2.33)
−1.603
0.109
Other biomarkers
PT (S)
13.2 (12.2, 14.4)
12.7 (12, 13.9)
−3.054
0.002
AFP (ng/mL)
3.67 (2.6, 6.5)
3.45 (2.36, 5.84)
−1.845
0.065
CD4/CD8
1.33 (1.02, 1.76)
1.26 (0.89, 1.73)
−1.641
0.101
Lipids, Blood glucose
FBG (mmol/L)
5.18 (4.85, 5.47)
5.14 (4.85, 5.5)
−0.601
0.548
TC (mmol/L)
4.59 (3.83, 5.2)
4.58 (3.96, 5.22)
−0.891
0.373
TG (mmol/L)
1.1 (0.82, 1.49)
1.07 (0.79, 1.52)
−0.281
0.779
HDL-C (mmol/L)
1.18 (1, 1.415)
1.2 (1.01, 1.43)
−0.666
0.506
LDL-C (mmol/L)
2.54 (2.02, 2.94)
2.46 (2.11, 3.05)
−0.611
0.541
Blood routine test
WBC (109/L)
5.01 (4.26, 6.01)
5 (4.13, 6.04)
−0.259
0.796
LY (109/L)
1.64 (1.28, 2)
1.68 (1.32, 2.04)
−0.656
0.512
MONO (109/L)
0.31 (0.24, 0.4)
0.32 (0.26, 0.41)
−0.769
0.442
NEUT (109/L)
2.89 (2.25, 3.6)
2.8 (2.16, 3.65)
−0.749
0.454
PLT (109/L)
159 (124, 202.5)
159 (122, 198)
−0.151
0.88
Renal function value
BUN (mmol/L)
4.48 (3.61, 5.2)
4.37 (3.6, 5.11)
−0.718
0.473
Cr (μmol/L)
70 (59.78, 80)
68 (60, 78)
−1.253
0.21
UA (μmol/L)
300 (256.5, 354)
303.5 (244, 352)
−0.37
0.712
The time interval between the start date of antiviral treatment and the enrollment date ≤90 days. APRI = (AST (U/L)/upper limit of normal value (U/L))/PLT (×109/L) ×100; FIB-4 = age (year) ×AST (U/L)/(PLT(×109/L) × ALT(U/L)1/2).
